Articles Archive - Page 295 of 332

Researchers Identify Molecule That Promotes Osteogenesis

Lara C. Pullen, PhD | October 19, 2015

New insights into bone cell biology—including the identification of parbendazole, a bone anabolic compound that promotes bone formation—may lead to better treatments for osteoporosis…

Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis

Will Boggs, MD | October 15, 2015

NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis. In the first study, online Sept. 21, Dr. Tamas Molnar…

FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz

Reuters Staff | October 14, 2015

(Reuters)—U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must be addressed in order…

60 Days to a Reciprocal Medical License in Nevada

Richard Quinn | October 14, 2015

A new law in Nevada streamlines medical licensure for physicians and could help rheumatologist recruitment efforts…

Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA

Michele B. Kaufman, PharmD, BCGP | October 14, 2015

In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…

Transatlantic Divide: How U.S. Pays Three Times More for Drugs

Reuters | October 13, 2015

LONDON (Reuters)—U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such…

Hospital Workers Often Transfer Germs When Removing Gloves, Gowns

Kathryn Doyle | October 12, 2015

(Reuters Health)—Fluorescent lotion and black light revealed that healthcare workers often contaminate their skin and clothing while removing their protective gear, researchers say. This contamination can spread germs and place the healthcare workers at risk for infection, the authors write in JAMA Internal Medicine. “It was surprising for the participants in the study to see…

Secukinumab Effective for Psoriatic Arthritis

Lara C. Pullen, PhD | October 12, 2015

A Phase 3 study found secukinumab may be an effective alternative to anti-TNF therapies for treating psoriatic arthritis, suggesting interleukin 17A may play a role in the disease…

Selena Gomez Says Suffered from Lupus, Underwent Chemotherapy

Reuters Staff | October 10, 2015

(Reuters)—Pop singer and actress Selena Gomez has revealed in an interview that she was diagnosed with the autoimmune disease lupus, which led to her canceling the end of her tour in 2013, but that the disease is now in remission. “I was diagnosed with lupus, and I’ve been through chemotherapy,” Gomez, 23, told Billboard magazine….

Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

Will Boggs, MD | October 9, 2015

NEW YORK (Reuters Health)—Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors is associated with a doubling of the risk of central nervous system demyelinating disease, researchers from Denmark report. “Based on the current evidence anti-TNF should be used cautiously in patients with an own or family history of demyelinating disease,” Dr. Nynne…